Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis

RZB is an effective and well-tolerated treatment for moderate-to-severe CD and UC, showing strong clinical and endoscopic outcomes, but further research is needed to assess long-term efficacy and safety.

Muhammad Waqas Afzal, A. Haseeb, Ushna Ali et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.